Epidemiology of invasive candidiasis and candidemia – a persistent problem

Czech version

Authors: Haber Jan ¹; Mallátová Naďa ²; Kolešková Evženie ¹; Hnátková Markéta ¹; Kořen Jan ¹; Herold Ivan ³
Authors‘ workplace: I. interní klinika – hematoonkologie VFN a 1. LF UK Praha ¹; Centrální laboratoře Nemocnice České Budějovice, a. s. ²; Anesteziologicko-resustitační oddělení, Oblastní nemocnice Mladá Boleslav, a. s. ³
Published in: Anest. intenziv. Med., 19, 2008, č. 2, s. 110-119
Category: Intensive Care Medicine - Original Paper

Overview

During the last decades fungal infections have become a serious complication with a significant impact on the length of hospital stay and mortality in hospitalized patients. Candida infections occur not only in neutropenic patients with haematological malignancies but also in patients with other forms of immune deficiency e.g. in those undergoing abdominal surgery, solid organ transplantations and those admitted to the ICU. The growing incidence of candida infections dates from the early 1980s to the late 1990s. The introduction of fluconazole resulted in a slow decrease in the incidence of candidiasis and a lower occurrence of Candida albicans infections, and a relatively higher incidence of infections caused by non- albicans Candida species. In spite of this the mortality remains high at 40-50% on some wards. In order to achieve better treatment results, better diagnostic tools and new antifungal agents are needed but greater awareness and better education of the medical staff are also essential.

Keywords:
invasive candidiasis – candidiasis – incidence – mortality – risk factors – candidemia – transplantation

Sources

1. Nucci, M., Anaissie, E. Revisiting the source of candidemia: skin or gut? Clin. Infect. Dis., 2001, 33, p. 1959–1967.

2. Pfaller, M. A., Diekema, D. J. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol., 2002, 40, p. 3551–3557.

3. Beck-Sagué, C., Jarvis, W. R. Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980–1990. National Infections Surveillance system. J. Infect. Dis., 1993, 167, p. 1247–1251.

4. Weinberger, M., Sacks, T., Sulkes, J., Shapiro, M., Polacheck, I. Increasing fungal isolation from clinical specimens: experience in a university hospital over a decade. J. Hosp. Infect., 1997, 35, 3, p. 185–195.

5. Banerjee, S. N., Emori, T. G., Culver, D. H. et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. National Nosocomial Infections Surveillance System. Am. J. Med., 1991, 16, 91, 3B, p. 86S–89S.

6. Pfaller, M., Wenzel, R. Impact of the changing epidemiology of fungal infections in the 90’s. Eur. J. Clin. Microbiol. Infect. Dis., 1992, 11, 4, p. 287–291.

7. Almirante, B., Rodriguez, D., Park, B. J. et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol., 2005, 43, 4, p. 1829–1835.

8. Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., Wenzel, R. P. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn. Microbiol. Infect. Dis., 1998, 30, p. 121–129.

9. Wisplinghoff, H., Bischoff, T., Tallent, S. M. et al. Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study. Clin. Infect. Dis., 2004, 39, p. 309–317.

10. Spencer, R. C. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur. J. Clin. Microbiol. Infect. Dis., 1996, 15, 4, p. 281–285.

11. Abi-Said, D., Anaissie, E., Uzun, O. et al. The epidemiology of hematogenous candidiasis by different Candida species. Clin. Infect. Dis., 1997, 24, p. 1122–1128.

12. Goodman, J. L., Winston, D. J., Greenfield, R. A. et.al. A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow Transplantation. N. Engl. J. Med., 1992, 326, 13, p. 845–851.

13. Gudlaugsson, O., Gillespie, S., Lee, K. et al. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis., 2003, 37, p. 1172–1177.

14. Sendid, B., Cotteau, A., François, F. et al. Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect. Dis., 2006, 6, p. 80–89.

15. Hobson, R. P. The global epidemiology of invasive Candida infections—is the tide turning? J. Hosp. Infect., 2003, 55, 3, p. 159–168.

16. McNeil, M. M., Nash, S. L., Hajjeh, R. A. et al. Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997. Clin. Infect. Dis., 2001, 33, p. 641–647.

17. Slavin, M. A., Osborne, B., Adams, R. et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. J. Infect. Dis., 1995, 171, 6, p. 1545–1552.

18. Marr, K. A., Seidel, K., White, T. C., Bowden, R. A. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the administration of prophylactic fluconazole. J. Infect. Dis., 2000, 181, p. 309–316.

19. Marr, K. A., Seidel, K., Slavin, M. A. et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogenetic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood, 2000, 96, 6, p. 2055–2061.

20. Marr, K. A. Invasive Candida Infections: The Changing Epidemiology. Oncology (Williston Park), 2004, 18, 14 (Suppl. 13), p. 9–14.

21. Pagano, L., Caiara, M., Nosari, A. et al. Fungal Infections in Recipients of Hematopoietic Stem Cell Transplants: Results of the SEIFEM B-2004 Study. Clin. Infect. Dis., 2007, 45, p. 1161–1170.

22. Trick, W. E., Fridkin, S. K., Edwards, J. R. et al. and National Nosocomial Infections Surveillance System Hospitals Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin. Infect. Dis., 2002, 35, p. 627–630.

23. Bedini, A., Venturell, C., Mussini, C. et al. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin. Microbiol. Infect., 2006, 12, 1, p. 75–80.

24. Rotstein, C., Bow, E. J., Lavardiere, M. et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin. Infect. Dis., 1999, 28, 2, p. 331–340.

25. Winston, D. J., Pakrasi, A., Busuttil, R. W. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med., 1999, 16, 131, 10, p. 729–737.

26. Pfaller, M. A., Diekema, D. J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev., 2007, 20, 1, p. 133–163.

27. Wey, S. B., Mori, M., Pfaller, M. A. et al. Hospital-acquired candidemia. Arch. Intern. Med., 1988, 148, p. 2642–2645.

28. Diekema, D. J., Messer, S. A., Brueggemann, A. B. et al. Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms Study. J. Clin. Microbiol., 2002, 40, 4, p. 1298–1302.

29. Hajjeh, R. A., Sofair, A. N., Harrison, L. H. et al. Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program. J. Clin. Microbiol., 2004, 42, 4, p. 1519–1527.

30. Weinberger, M., Leibovici, L., Perez, S. et al. Characteristics of candidaemia with Candida-albicans compared with non-albicans Candida species and predictors of mortality. J. Hosp. Infect., 2005, 61, 2, p. 146–154.

31. Ben-Abraham, R., Keller, N., Teodorovitch, N. et al. Predictors of adverse outcome from candidal infection in a tertiary care hospital. J. Infect., 2004, 49, 4, p. 317–323.

32. Asmundsdottir, L. R., Erlendsdottir, H., Gottfredsson, M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J. Clin. Microbiol., 2002, 40, p. 3489–3492.

33. Poikonen, E., Lyytikäinen, O., Anttila, V. J., Ruutu, P. Candidemia in Finland, 1995–1999. Emerg. Infect. Dis., 2003, 9, 8, p. 985–990.

34. Sandven, P. L., Bevanger, A., Digranes, P. et al. Constant low rate of fungemia in Norway, 1991 to 1996. J. Clin. Microbiol., 1998, 36, 12, p. 3455–3459.

35. Richet, H., Roux, P., Des Champs, C. et al. and French Candidemia Study Group Candidemia in French hospitals: incidence rates and characteristics. Clin. Microbiol. Infect., 2002, 8, p. 405–412.

36. Martin, D., Persat, F., Piens, M. A., Picot, S. Candida species distribution in bloodstream cultures in Lyon, France, 1998–2001. Eur. J. Clin. Microbiol. Infect. Dis., 2005, 24, p. 329–333.

37. Rodriguez, D., Almirante, B., Park, B. et al. Candidemia in Neonatal Intensive Care Units: Barcelona. Spain Pediatric Inf. Disease J., 2006, 25, 3, p. 224–229.

38. Kao, A. S., Brandt, M. E., Pruitt, W. R. et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis.,1999, 29, p. 1164–1170.

39. Yamamura, D. L., Rotstein, C., Nicolle, L. E., Ioannou, S. Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992–1994. Can. Med. Assoc. J., 1999, 23,160, 4, p. 493–499.

40. Pfaller, M. A., Jones, R. N., Doern, G. V. et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. J. Clin. Microbiol., 1998, 36, 7, p. 1886–1889.

41. Pretti, N., Malani, Suzanne F., Bradley, Rhonda S., Little, Carol A., Kauffman Trends in species causing fungaemia in a tertiary care medical centre over 12 years. Mycoses, 2001, 44, 11–12, p. 446–449.

42. Bodey, G. P., Mardani, M., Hanna, H. et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am. J. Med., 2002, 112, 5, p. 380–385.

43. Antoniadou, A., Torres, H. A., Lewis, R. P. et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore), 2003, 82, 5, p. 309–321.

44. Pfaller, M. A., Jones, R. N., Doern, G. V. et al. Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997–1998. Antimicrob. Agents Chemother., 2000, 44, 3, p. 747–751.

45. Pfaller, M. A., Jones, R. N., Doern, G. V. et al. International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn. Microbiol. Infect. Dis., 1999, 35, 1, p. 19–25.

46. Luzzati, R., Amalfitano, G., Lazzarini, L. et al. Nosocomial candidemia in non–neutropenic patients at an Italian tertiary care hospital. Eur. J. Clin. Microbiol. Infect. Dis., 2000, 19, 8, p. 602–607.

47. Pappas, P. G., Rex, J. H., Lee, J. et al. A Prospective Observational Study of Candidemia: Epidemiology, Therapy, and Influences on Mortality in Hospitalized Adult and Pediatric Patients. Clin. Infect. Dis., 2003, 37, p. 634–643.

48. Pemán, J., Cantón, E., Gobernado, M. and the Spanish ECMM Working Group on Candidaemia Eur. J. Clin. Microbiol. Infect. Dis., 2005, 24, p. 23–30.

49. Marchetti, O., Bille, J., Fluckiger, U. et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin. Infect. Dis., 2004, 38, p. 311–320.

50. Viscoli, C., Girmenia, C., Marinus, A. et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis., 1999, 28, p. 1071–1079.

51. Viudes, A., Peman, J., Canton, E. et al. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur. J. Clin. Microbiol. Infect. Dis., 2002, 21, p. 767–774.

52. Kibbler, C. C., Seaton, S., Barnes, R. A. et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J. Hosp. Infect., 2003, 54, 1, p. 18–24.

53. Cuenca-Estrella, M., Rodriguez, D., Almirante, B. et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002–2003. J. Antimicrob. Chemother., 2005, 55, 2, p. 194–199.

54. Arendrup, M. C., Fuursted, K., Gahrn-Hansen, B. et al. Seminational Surveillance of Fungemia in Denmark: Notably High Rates of Fungemia and Numbers of Isolates with Reduced Azole Susceptibility. J. Clin. Microbiol., 2005, 43, 9, p. 4434–4440.

55. Buchta, V., Kolář, M., Bergerová, T. et al. Výskyt potenciálně patogenních kvasinek v krvi a moči pacientů ve velkých nemocnicích v České republice. Klin. Mikrobiol. Inf. Lék., 1998, 4, p. 10–17.

56. Hamal, P., Dobiášová, S., Kocmanová, I. Candidemia in large Czech hospitals, 2000–2002: an epidemiological study. 15th Congress of the International Society for Human and Animal Mycology, San Antonio, 2003, p. 463.

57. Hamal, P., Kocmanová, I., Jedličková, A. et al. Epidemiological analysis of candidemia in Czech tertiary care hospitals in 2000–2006. J. Chemother., 2007, 19, (Suppl. 3), p. S61–S62.

58. Montravers, P., Jabbour, K. Clinical consequences of resistant Candida infections in intensive care. Int. J. Antimicrob. Agents, 2006, 27, 1, p. 1–6.

59. Pagano, L., Mele, L., Fianchi, L. et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica, 2002, 87, p. 535–541.

60. Vincent, J. L., Anaissie, E., Bruining, H. et al. Epidemiology, diagnosis and treatment of systemic candida infection in surgical patients under intensive care. Intensive Care Med., 1998, 24, p. 206–216.

Labels

Anaesthesiology, Resuscitation and Inten Intensive Care Medicine

The theory and simplified mathematical model of multi-level intermittent positive pressure ventilation

Tri-level pulmonary ventilation (3LV®) – initial clinical experience

LMA-ProSeal™ laryngeal mask is a safe option for securing the airways for laparoscopic cholecystectomy

Intramuscular dexmedetomidine in burns victims – preliminary results

Dexmedetomidine-ketamine intravenous sedation during local anaesthesia

Classification of infections in intensive care and a comparison of their incubation period and carrier status

Article was published in

Anaesthesiology and Intensive Care Medicine

2008 Issue 2